Immatics (NASDAQ:IMTX) Receives “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Immatics (NASDAQ:IMTX) in a report issued on Thursday, Benzinga reports.

Separately, Mizuho raised their price target on Immatics from $14.00 to $16.00 and gave the company a buy rating in a report on Thursday, May 16th.

Immatics Stock Performance

Shares of IMTX opened at $11.73 on Thursday. Immatics has a fifty-two week low of $7.15 and a fifty-two week high of $13.77. The firm’s 50-day simple moving average is $11.77 and its two-hundred day simple moving average is $11.58. The stock has a market cap of $993.04 million, a PE ratio of -11.07 and a beta of 0.75.

Immatics (NASDAQ:IMTX) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.17. The company had revenue of $20.19 million for the quarter, compared to the consensus estimate of $12.36 million. Immatics had a negative return on equity of 23.34% and a negative net margin of 103.99%. Equities research analysts predict that Immatics will post -1.03 EPS for the current year.

Hedge Funds Weigh In On Immatics

Hedge funds have recently added to or reduced their stakes in the company. Quarry LP purchased a new stake in Immatics during the 2nd quarter valued at $99,000. Forefront Analytics LLC bought a new stake in Immatics in the 2nd quarter worth about $139,000. Nan Fung Group Holdings Ltd purchased a new position in Immatics in the 1st quarter worth about $165,000. ADAR1 Capital Management LLC bought a new position in Immatics during the 4th quarter valued at about $232,000. Finally, AlphaCentric Advisors LLC boosted its holdings in shares of Immatics by 14.3% during the 2nd quarter. AlphaCentric Advisors LLC now owns 20,000 shares of the company’s stock valued at $232,000 after acquiring an additional 2,500 shares during the last quarter. 64.41% of the stock is currently owned by hedge funds and other institutional investors.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.